Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
British Journal of Haematology
|
April 28, 2016
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
Juan M Bergua, Pau Montesinos, David Martinez-Cuadrón, et al.
Leukemia & Lymphoma
|
June 14, 2021
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients
Blanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, et al.
Revista Espanola De Anestesiologia Y Reanimacion
|
May 18, 2022
Recommendations of the Society of Thoracic Surgery and the Section of Cardiothoracic and Vascular Surgery of the Spanish Society of Anesthesia, Resuscitation and Pain Therapy, for patients undergoing lung surgery included in an intensified recovery program
I Garutti, A Cabañero, R Vicente, et al.
Revista Espanola De Anestesiologia Y Reanimacion
|
July 23, 2021
Recommendations of the Society of Thoracic Surgery and the Section of Cardiothoracic and Vascular Surgery of the Spanish Society of Anesthesia, Resuscitation and Pain Therapy, for patients undergoing lung surgery included in an intensified recovery program
I Garutti, A Cabañero, R Vicente, et al.
Cancer
|
February 24, 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
Susana Vives, David Martínez-Cuadrón, Juan Bergua Burgues, et al.
Blood Cancer Journal
|
May 12, 2023
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Claudia Sargas, Rosa Ayala, María J Larráyoz, et al.
Leukemia
|
October 20, 2020
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, et al.
Haematologica
|
May 18, 2023
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
David Martínez-Cuadrón, Juan E Megías-Vericat, Cristina Gil, et al.
Cancer
|
June 19, 2024
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Jorge Labrador, David Martínez-Cuadrón, Blanca Boluda, et al.
Scientific Reports
|
October 21, 2021
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Tamara Castaño-Bonilla, Juan M Alonso-Dominguez, Eva Barragán, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
British Journal of Haematology
|
April 28, 2016
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia
Juan M Bergua, Pau Montesinos, David Martinez-Cuadrón, et al.
Leukemia & Lymphoma
|
June 14, 2021
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients
Blanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, et al.
Revista Espanola De Anestesiologia Y Reanimacion
|
May 18, 2022
Recommendations of the Society of Thoracic Surgery and the Section of Cardiothoracic and Vascular Surgery of the Spanish Society of Anesthesia, Resuscitation and Pain Therapy, for patients undergoing lung surgery included in an intensified recovery program
I Garutti, A Cabañero, R Vicente, et al.
Revista Espanola De Anestesiologia Y Reanimacion
|
July 23, 2021
Recommendations of the Society of Thoracic Surgery and the Section of Cardiothoracic and Vascular Surgery of the Spanish Society of Anesthesia, Resuscitation and Pain Therapy, for patients undergoing lung surgery included in an intensified recovery program
I Garutti, A Cabañero, R Vicente, et al.
Cancer
|
February 24, 2021
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
Susana Vives, David Martínez-Cuadrón, Juan Bergua Burgues, et al.
Blood Cancer Journal
|
May 12, 2023
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Claudia Sargas, Rosa Ayala, María J Larráyoz, et al.
Leukemia
|
October 20, 2020
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, et al.
Haematologica
|
May 18, 2023
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
David Martínez-Cuadrón, Juan E Megías-Vericat, Cristina Gil, et al.
Cancer
|
June 19, 2024
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Jorge Labrador, David Martínez-Cuadrón, Blanca Boluda, et al.
Scientific Reports
|
October 21, 2021
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Tamara Castaño-Bonilla, Juan M Alonso-Dominguez, Eva Barragán, et al.
Page
of 3